Arcutis Biotherapeutics (ARQT) Operating Expenses (2019 - 2026)

Arcutis Biotherapeutics' Operating Expenses history runs 8 years deep, the most recent figure standing at $114.5 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 26.68% year-over-year to $114.5 million; the TTM figure through Mar 2026 stood at $412.4 million (up 23.43% YoY), while the FY2025 annual figure was $388.3 million, up 19.5% from the prior year.
• Operating Expenses for Q1 2026 stood at $114.5 million, up from $111.1 million in the prior quarter.
• The five-year high for Operating Expenses was $114.5 million in Q1 2026, with the low at $62.6 million in Q1 2022.
• The 5-year median for Operating Expenses is $80.9 million (2024), against an average of $84.3 million.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses jumped 84.79% in 2022, then slipped 28.88% in 2023.
• Arcutis Biotherapeutics' Operating Expenses stood at $71.4 million in 2022, then rose by 4.64% to $74.7 million in 2023, then gained by 5.75% to $79.0 million in 2024, then jumped by 40.67% to $111.1 million in 2025, then grew by 3.03% to $114.5 million in 2026.
• Business Quant data shows ARQT's Operating Expenses at $114.5 million in Q1 2026, $111.1 million in Q4 2025, and $90.7 million in Q3 2025.